Q2 2022 Earnings Estimate for West Pharmaceutical Services, Inc. Issued By KeyCorp (NYSE:WST)

West Pharmaceutical Services, Inc. (NYSE:WSTGet Rating) – Equities research analysts at KeyCorp cut their Q2 2022 earnings per share (EPS) estimates for West Pharmaceutical Services in a research note issued on Thursday, April 28th. KeyCorp analyst P. Knight now expects that the medical instruments supplier will earn $2.20 per share for the quarter, down from their previous estimate of $2.29. KeyCorp also issued estimates for West Pharmaceutical Services’ Q3 2022 earnings at $2.30 EPS, FY2022 earnings at $9.31 EPS, FY2023 earnings at $9.90 EPS and FY2024 earnings at $10.90 EPS.

West Pharmaceutical Services (NYSE:WSTGet Rating) last released its earnings results on Thursday, April 28th. The medical instruments supplier reported $2.30 earnings per share for the quarter, topping the consensus estimate of $2.12 by $0.18. The company had revenue of $720.00 million for the quarter, compared to the consensus estimate of $720.92 million. West Pharmaceutical Services had a net margin of 23.76% and a return on equity of 30.80%. West Pharmaceutical Services’s revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.05 EPS.

Several other analysts have also recently commented on WST. StockNews.com cut shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Thursday. Zacks Investment Research cut shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating and set a $450.00 price objective for the company. in a research note on Saturday, January 8th. Finally, William Blair restated an “outperform” rating on shares of West Pharmaceutical Services in a research note on Tuesday, February 22nd.

NYSE:WST opened at $315.06 on Monday. The company has a market cap of $23.43 billion, a PE ratio of 35.01, a P/E/G ratio of 3.64 and a beta of 1.06. West Pharmaceutical Services has a twelve month low of $308.36 and a twelve month high of $475.35. The company has a current ratio of 2.93, a quick ratio of 2.30 and a debt-to-equity ratio of 0.09. The company’s 50 day moving average is $384.72 and its two-hundred day moving average is $406.16.

Several institutional investors and hedge funds have recently bought and sold shares of WST. Vancity Investment Management Ltd raised its position in West Pharmaceutical Services by 7.6% during the first quarter. Vancity Investment Management Ltd now owns 16,399 shares of the medical instruments supplier’s stock worth $6,735,000 after acquiring an additional 1,165 shares during the period. Whittier Trust Co. raised its position in West Pharmaceutical Services by 6.3% during the first quarter. Whittier Trust Co. now owns 29,220 shares of the medical instruments supplier’s stock worth $12,001,000 after acquiring an additional 1,733 shares during the period. Whittier Trust Co. of Nevada Inc. raised its position in West Pharmaceutical Services by 17.0% during the first quarter. Whittier Trust Co. of Nevada Inc. now owns 14,398 shares of the medical instruments supplier’s stock worth $5,914,000 after acquiring an additional 2,095 shares during the period. SG Americas Securities LLC raised its position in West Pharmaceutical Services by 16.2% during the first quarter. SG Americas Securities LLC now owns 7,059 shares of the medical instruments supplier’s stock worth $2,899,000 after acquiring an additional 982 shares during the period. Finally, Park Avenue Securities LLC raised its position in West Pharmaceutical Services by 5.1% during the first quarter. Park Avenue Securities LLC now owns 11,224 shares of the medical instruments supplier’s stock worth $4,610,000 after acquiring an additional 548 shares during the period. Hedge funds and other institutional investors own 91.24% of the company’s stock.

In related news, VP Quintin J. Lai sold 8,016 shares of the business’s stock in a transaction on Monday, March 14th. The shares were sold at an average price of $371.69, for a total value of $2,979,467.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.66% of the company’s stock.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 3rd. Shareholders of record on Wednesday, July 20th will be paid a dividend of $0.18 per share. This represents a $0.72 annualized dividend and a yield of 0.23%. The ex-dividend date is Tuesday, July 19th. West Pharmaceutical Services’s payout ratio is 8.00%.

West Pharmaceutical Services Company Profile (Get Rating)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

See Also

Earnings History and Estimates for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.